SCHEMBL4416482

SCHEMBL4416482

CCOC(=O)COc1ccc(NCC(=O)OC(C)(C)C)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.46
CASP7 P55210 1/20 0.46
CASP9 P55211 1/20 0.46
KDM4E B2RXH2 7/20 0.42
CDC25B P30305 1/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TLR9 Q9NR96 2/20 0.41
MITF O75030 1/20 0.41
HSP90AA1 P07900 1/20 0.41
PKM P14618 1/20 0.41
USP2 O75604 1/20 0.41
PTPN1 P18031 1/20 0.41
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421726 0.85 CASP3 (0.47) CASP3CASP7CASP9KDM4ECDC25B
SCHEMBL4421619 0.80 CASP3 (0.54) CASP3CASP7CASP9KDM4ECDC25B
SCHEMBL4861306 0.77 ESR1 (0.49) KDM4EALDH1A1MAPTHPGDMAPK1
SCHEMBL4416487 0.75 CASP3 (0.46) CASP3CASP7CASP9KDM4EALDH1A1
SCHEMBL4861392 0.75 FFAR1 (0.45) LMNA
SCHEMBL4860553 0.75 ALDH1A1 (0.53) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL4860643 0.75 RORC (0.46) KDM4EALDH1A1MAPTHPGDNPSR1
SCHEMBL27557341 0.74 CDC25B (0.40) KDM4ECDC25BGAANPC1RAB9A
SCHEMBL4422051 0.73 CASP3 (0.61) CASP3CASP7CASP9KDM4ECDC25B
SCHEMBL4859929 0.73 POLB (0.46) KDM4EALDH1A1MAPTMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495001-B2 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
EP-1682507-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
WO-2005049572-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 WO disclosed
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG CASP3 718/4885CASP7 1348/4885CASP9 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.